We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LAWMAKERS WORKING TOWARD COMPROMISE ON BIOTECH FUNDING DISPUTE

LAWMAKERS WORKING TOWARD COMPROMISE ON BIOTECH FUNDING DISPUTE

July 13, 2006

More venture capital-backed biotech firms could become eligible for federal research funding under a compromise being worked out by Senate Republicans.

Sen. Olympia Snowe (R-Maine), the chairwoman of the Small Business and Entrepreneurship Committee, will be working with other Republican lawmakers and the Biotechnology Industry Organization (BIO) to decide how to allow biotech firms with venture capital backing to receive federal funds reserved for small businesses. At issue is R&D funding awarded under the Small Business Administration's Small Business Innovation Research Program (SBIR), which accounts for approximately $2 billion in grants annually.

Companies with more than 49 percent ownership by venture capitalists are currently not eligible for SBIR funds. Biotech companies and lawmakers such as Sen. Kit Bond (R-Mo.) argue that these funds are essential to these companies' competitiveness in the marketplace.

Snowe will work to modify Bond's bill S.1263, which amends the Small Business Act (SBA), to make companies with majority venture capital ownership eligible for the funds. "Hopefully we'll find that middle ground" between allowing more firms with venture capital ownership and making eligibility so broad that the companies that currently do not qualify as small businesses become eligible for the SBIR funds, Snowe said after a July 12 hearing on the bill.

The lawmaker wants to determine how to define an "investor" for the purposes of SBIR and decide whether companies supported by individual or multiple venture capitalists should be allowed to receive these funds. Snowe is hoping to address the issue in her committee by the end of July, with an eye toward reauthorization of the SBA by Oct. 1.

Not receiving these funds would be "a major setback," for the biotech industry, Bond said during the hearing. The biotech industry "is like no other in the world" because of the time and money necessary to get products to market, he added, necessitating supplemental funding.

But critics, including the Small Business Technology Council, argue that these funds are better spent on companies that lack the financial backing of venture capitalists. Modifying the definition of a small business is "a slippery slope" that would push legitimately small businesses out of the running for these funds, Gene Watson, program manager of the Wyoming SBIR/STTR (small business technology transfer) Initiative, said.

However, BIO believes that the program "makes us competitive," Lauren Choi, BIO's director of policy, capital formation and emerging companies, said. It is "critical" that SBIR amendments are included in the SBA reauthorization, she said. (http://www.fdanews.com/did/5_136/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing